Dow-Chung Chi Selected Research

Disease Progression

1/2018

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dow-Chung Chi Research Topics

Disease

2	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2020
1	Neoplasms (Cancer) 08/2021
1	Breast Neoplasms (Breast Cancer) 08/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Melanoma (Melanoma, Malignant) 01/2018
1	Disease Progression 01/2018
1	Leiomyosarcoma 12/2017
1	Liposarcoma 12/2017
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2012
1	Dyspnea (Shortness of Breath) 09/2012
1	Pancreatic Neoplasms (Pancreatic Cancer) 09/2012
1	Pneumonia (Pneumonitis) 09/2012

Drug/Important Bio-Agent (IBA)

2	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 01/2020
1	ruxolitinibIBA 08/2021
1	Trastuzumab (Herceptin)FDA Link 08/2021
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2021
1	enzalutamideIBA 01/2020
1	apalutamideIBA 01/2020
1	darolutamideIBA 01/2020
1	AntibodiesIBA 01/2018
1	TrabectedinIBA 12/2017
1	AnthracyclinesIBA 12/2017
1	Cytotoxins (Cytolysins)IBA 09/2012
1	Gemcitabine FDA Link 09/2012

Therapy/Procedure

2	Therapeutics 08/2021 - 01/2018
2	Castration 01/2021 - 01/2020
1	Immunotherapy 01/2018